Tien Liang Biotech Co

Tien Liang Biotech Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Tien Liang Biotech Co (4127.TWO) as of Nov 19, 2026 is 39.95 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 377.92 % — a change of -89.43% (lower).

FCF Conversion

39.95 %

YoY

-89.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Tien Liang Biotech Co is 2025 39.95 % . FCF Conversion Rate (FCF/EBITDA) of Tien Liang Biotech Co was 2024 377.92 % . It decreases by -89.43% lower compared to the previous year.

The Tien Liang Biotech Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
56.30 TWD
Jan 1, 2018
26.92 TWD
Jan 1, 2020
23.85 TWD
Jan 1, 2021
95.72 TWD
Jan 1, 2022
35.09 TWD
Jan 1, 2023
362.77 TWD
Jan 1, 2024
377.92 TWD
Jan 1, 2025
39.95 TWD
The Tien Liang Biotech Co FCF Conversion history
YEARFCF ConversionYoY
39.95 %-89.43%
377.92 %+4.18%
362.77 %+933.91%
35.09 %-63.34%
95.72 %+301.38%
23.85 %-11.42%
26.92 %-52.18%
56.30 %-48.76%
109.87 %-11.22%
123.75 %+105.29%
60.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tien Liang Biotech Co Stock analysis

What does Tien Liang Biotech Co do? Tien Liang BioTech Co. Ltd. manufactures and sells Chinese herbal and western medicine, including active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicines. The company imports, wholesales, and retails western medicines domestically. Its products are distributed within the domestic market, targeting healthcare providers and consumers seeking traditional and modern pharmaceutical solutions. The firm's revenue streams come from the sale of manufactured medicines, APIs, biopharmaceuticals, and retail distribution of western medicines. Domestic market sales form the core of its business, with no mention of international distribution channels. The company serves both the traditional Chinese medicine segment and the modern pharmaceutical segment through its comprehensive product portfolio. Tien Liang BioTech operates within the pharmaceutical manufacturing and distribution sector, focusing on domestic sales of herbal, western, and biopharmaceutical products. Its business model integrates manufacturing, import, wholesale, and retail operations to serve the local healthcare market. Tien Liang Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tien Liang Biotech Co stock

FCF Conversion Rate (FCF/EBITDA) of Tien Liang Biotech Co is 39.95 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Tien Liang Biotech Co changed from 377.92 % to 39.95 %, representing a -89.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Tien Liang Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Tien Liang Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Tien Liang Biotech Co

All Key Metrics — Tien Liang Biotech Co